Change - Announcement of Appointment::Announcement of Appointment of Chairman of the Board

Issuer & Securities

Issuer/ Manager
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
Securities
TIANJIN PHARM DA REN TANG GRP - CNE100000924 - T14
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
26-Nov-2024 18:29:20
Status
New
Announcement Sub Title
Announcement of Appointment of Chairman of the Board
Announcement Reference
SG241126OTHRSPL5
Submitted By (Co./ Ind. Name)
Jiao Yan
Designation
Secretary to the Board
Description (Please provide a detailed description of the event in the box below)
Announcement of Appointment of Chairman of the Board

Additional Details

Date Of Appointment
26/11/2024
Name Of Person
Wang Lei
Age
53
Country Of Principal Residence
China
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Approved

Please refer to the separate announcement dated 26 November 2024 made by the Company in relation to the resolutions passed at the 9th Board meeting for FY2024 for further details on Ms. Wang s resume.

The Nomination Committee of the Company, upon review of Ms. Wang s resume, agreed with the proposed election of Ms. Wang as Chairman of the Board.
Whether appointment is executive, and if so, the area of responsibility
Duties as Chairman of the Board and an Executive Director of the Company
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chairman of the Board and an Executive Director
Professional qualifications
Ms. Wang Lei is a Senior Engineer (Professor Level) and holds a postgraduate degree and a Doctorate in Engineering.
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
From January 2022 to August 2022, Ms. Wang Lei worked as Deputy General Manager of TPH Marketing Management Center.
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
Ms. Wang has been with Company since July 1993 and has successively worked at Darentang Pharmaceutical Factory, the Planning Office of the Chinese Patent Medicine Department of the Company, the Industrial Department of the Company, and Lerentang Pharmaceutical Factory. Between May 2013 and June 2013, she was a member of the Supervisory Committee of the Company, and from June 2013 to March 2018, she successively served as Deputy General Manager and General Manager of the Company. Ms. Wang was appointed as a Director of the Company for the period from May 2015 to May 2018. Since March 2018, she successively served as Executive Deputy General Manager, General Manager, and Deputy Chairman of Jingwanhong Pharmaceutical. From January 2022 to August 2022, Ms. Wang worked as Deputy General Manager of the Marketing Management Center of Tianjin Pharmaceutical Holdings Co., Ltd. ( TPH ). Since August 2022, she has been serving as General Manager of the Company, and since December 2022, she has also been a Director of the Company.
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Ms. Wang Lei was an executive director of the Company for the period from May 2015 to May 2018.
Present
Since December 2022, she has also been an Executive Director of the Company.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
Yes
If Yes, Please provide details of prior experience
Ms. Wang Lei was an executive director of the Company for the period from May 2015 to May 2018.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.